Cargando…

Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study

OBJECTIVE: To assess the efficacy and safety of ribavirin and interferon-α (RBV/IFN-α) therapy in COVID-19 patients. METHODS: A multicenter, retrospective cohort study of COVID-19 patients admitted to 4 hospitals in Hubei Province, China, from 31 December 2019 to 31 March 2020. Patients were divided...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hui, Xiong, Nian, Li, Changjun, Gong, Yanhong, Liu, Li, Yang, Heping, Tan, Xiangping, Jiang, Nan, Zong, Qiao, Wang, Jing, Lu, Zuxun, Yin, Xiaoxv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840408/ https://www.ncbi.nlm.nih.gov/pubmed/33515771 http://dx.doi.org/10.1016/j.ijid.2021.01.055

Ejemplares similares

Effectiveness of Systemic Corticosteroids Therapy for Nonsevere Patients With COVID-19: A Multicenter, Retrospective, Longitudinal Cohort Study
por: Chen, Zhenyuan, et al.
Publicado: (2022)

Sex-Disaggregated Data on Clinical Characteristics and Outcomes of Hospitalized Patients With COVID-19: A Retrospective Study
por: Wang, Mengdie, et al.
Publicado: (2021)

Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study
por: Jiang, Nan, et al.
Publicado: (2021)

Evaluation of early antibiotic use in patients with non‐severe COVID‐19 without bacterial infection
por: Yin, Xiaoxv, et al.
Publicado: (2022)

Evaluation of the Quality of Antibiotic Prescribing in Primary Care: A Multicenter Longitudinal Study From Shenzhen, China
por: Gong, Yanhong, et al.
Publicado: (2021)

Prevalence and determinants of smoking behavior among physicians in emergency department: A national cross-sectional study in China
por: Zong, Qiao, et al.
Publicado: (2022)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

A Systematic Review of Antibiotic Prescription Associated With Upper Respiratory Tract Infections in China
por: Li, Jing, et al.
Publicado: (2016)

Factors associated with doctors’ knowledge on antibiotic use in China
por: Bai, Yu, et al.
Publicado: (2016)

The Mediating Effects of Stigma on Depressive Symptoms in Patients With Tuberculosis: A Structural Equation Modeling Approach
por: Qiu, Lei, et al.
Publicado: (2018)

Over-the-counter antibiotic sales in community and online pharmacies, China
por: Gong, Yanhong, et al.
Publicado: (2020)

Antimicrobial resistance in Neisseria gonorrhoeae in China: a meta-analysis
por: Chen, Yawen, et al.
Publicado: (2016)

Development trend of primary healthcare after health reform in China: a longitudinal observational study
por: Feng, Jie, et al.
Publicado: (2022)

Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro
por: Teng, Lichen, et al.
Publicado: (2014)

Prevalence of depressive symptoms and work-related risk factors among nurses in public hospitals in southern China: A cross-sectional study
por: Gong, Yanhong, et al.
Publicado: (2014)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Intravenous thrombolytic therapy for acute ischemic stroke in Hubei, China: a survey of thrombolysis rate and barriers
por: Zhou, Yanfeng, et al.
Publicado: (2019)

Serous Retinal Detachments Complicating Interferon-α and Ribavirin Treatment in Patients with Hepatitis C
por: Modorati, Giulio, et al.
Publicado: (2011)

Efficacy of Interferon α-2b and Ribavirin against West Nile Virus In Vitro
por: Anderson, John F., et al.
Publicado: (2002)

Role of MicroRNA Modulation in the Interferon-α/Ribavirin Suppression of HIV-1 In Vivo
por: Abdel-Mohsen, Mohamed, et al.
Publicado: (2014)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
por: Zeng, Yan-Ming, et al.
Publicado: (2020)

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
por: Falzarano, Darryl, et al.
Publicado: (2013)

Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
por: Turker, Kamuran, et al.
Publicado: (2015)

Chinese Version of the EQ-5D Preference Weights: Applicability in a Chinese General Population
por: Wu, Chunmei, et al.
Publicado: (2016)

The association of metabolic syndrome components and diabetes mellitus: evidence from China National Stroke Screening and Prevention Project
por: Li, Wenzhen, et al.
Publicado: (2019)

Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study
por: Arabi, Yaseen M, et al.
Publicado: (2020)

Job satisfaction and its related factors among emergency department physicians in China
por: Li, Kang, et al.
Publicado: (2022)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C
por: Rathi, Chetan, et al.
Publicado: (2015)

Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon α — hype or hope?
por: Vogel, Wolfgang
Publicado: (2004)

Clinical Outcomes of Japanese Encephalitis after Combination Treatment of Immunoglobulin, Ribavirin, and Interferon-α2b
por: Son, Hyoshin, et al.
Publicado: (2021)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
por: Huang, Yin-Qiu, et al.
Publicado: (2020)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_998ueu3v02461h9ga3te3nq95o